EGFR and non-small cell lung carcinoma: Further cotreating gefitinib and 3-MA, a dual inhibitor of PI3K and autophagy, significantly inhibited the cell growth of TKI-resistant NSCLC cells (CL68 and H1975, supplemental Fig. S5A) and decreased the LC3-II protein level, though the EGFR degradation was not rescued (supplemental Fig. S5, B and C).